CPT-11 (Irinotecan) - Revision history

Lazy at 08:27, 18 January 2025

2025-01-18T08:27:01Z

← Older revision		Revision as of 01:27, 18 January 2025
Line 15:		Line 15:
	\|book_text=Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas.		\|book_text=Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas.
	\|treatment_category=Other chemotherapy agents at recurrence		\|treatment_category=Other chemotherapy agents at recurrence
	}}		\|overview=CPT-11 (Irinotecan) is an FDA-approved drug for colon cancer that is currently under investigation for the treatment of recurrent glioblastoma multiforme (GBM) and other malignant gliomas, showing promising results in early-phase trials when combined with therapies like Bevacizumab and Temozolomide. While it has demonstrated potential improvements in patient outcomes, the treatment is associated with manageable but significant toxicities, emphasizing the need for further research to optimize its use.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:42:52Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:42, 12 November 2024
Line 14:		Line 14:
	\|toxicity_explanation=While showing promise in efficacy, the combination treatments involving CPT-11 have been associated with manageable but significant toxicities, including hematologic, gastrointestinal, and hepatic adverse events.		\|toxicity_explanation=While showing promise in efficacy, the combination treatments involving CPT-11 have been associated with manageable but significant toxicities, including hematologic, gastrointestinal, and hepatic adverse events.
	\|book_text=Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas.		\|book_text=Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas.
	\|~~category~~=Other chemotherapy agents at recurrence		\|treatment_category=Other chemotherapy agents at recurrence
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=CPT-11 (Irinotecan) |FDA_approval=Approved for the treatment of colon cancer; under investigation for recurrent glioma |used_for=Recurrent Glioblastoma Multiforme (GBM) and other malignant gliomas |clinical_trial_phase=Phase I/II trials in combination with other therapies |common_side_effects=Hematologic, gastrointestinal, and hepatic toxicities noted; acceptable safety profile in combination regimens |OS_without=Not directly specified; histori..."

2024-03-31T04:49:58Z

Created page with "{{TreatmentInfo |drug_name=CPT-11 (Irinotecan) |FDA_approval=Approved for the treatment of colon cancer; under investigation for recurrent glioma |used_for=Recurrent Glioblastoma Multiforme (GBM) and other malignant gliomas |clinical_trial_phase=Phase I/II trials in combination with other therapies |common_side_effects=Hematologic, gastrointestinal, and hepatic toxicities noted; acceptable safety profile in combination regimens |OS_without=Not directly specified; histori..."

New page

{{TreatmentInfo
|drug_name=CPT-11 (Irinotecan)
|FDA_approval=Approved for the treatment of colon cancer; under investigation for recurrent glioma
|used_for=Recurrent Glioblastoma Multiforme (GBM) and other malignant gliomas
|clinical_trial_phase=Phase I/II trials in combination with other therapies
|common_side_effects=Hematologic, gastrointestinal, and hepatic toxicities noted; acceptable safety profile in combination regimens
|OS_without=Not directly specified; historical control data needed for comprehensive comparison
|OS_with=Increases observed in specific combination trials, such as Irinotecan with Bevacizumab
|PFS_without=Variable across studies
|PFS_with=Enhancements in progression-free survival noted in combination therapies, ranging from improvement in median progression-free survival times to higher 6-month survival rates
|usefulness_rating=Under investigation; early results promising, especially in combination therapies
|usefulness_explanation=The combination of CPT-11 with agents like Bevacizumab and Temozolomide has shown potential in treating recurrent malignant gliomas, suggesting a meaningful clinical benefit in this challenging patient population.
|toxicity_level=3
|toxicity_explanation=While showing promise in efficacy, the combination treatments involving CPT-11 have been associated with manageable but significant toxicities, including hematologic, gastrointestinal, and hepatic adverse events.
|book_text=Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas.
|category=Other chemotherapy agents at recurrence
}}